microRNA Replacement Therapy
Press Releases

 
Press Releases
Date Title and Summary View
03-14-17 AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq: MIRN), a biopharmaceutical company, today reported financial results for the fourth quarter and year ended December 31, 2016 and provided a corporate update. Following its November 2016 decision to discontinue all research and ...
05-09-17 AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a biopharmaceutical company, today reported financial results for the first quarter of 2017 and provided a corporate update. Following its late 2016 discontinuation of all research and development activities, the Com...
05-16-17 - Transaction Expected to Advance Synlogic's Innovative Platform for the Discovery and Development of Novel Synthetic Biotic™ Medicines - - Synlogic Closes $42 Million of Series C Preferred Stock Financing by Leading Biotechnology Investors - - Combined Company Well-Capitaliz...
08-25-17 AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Mirna) (NASDAQ: MIRN) announced today that, based upon the final vote count certified by the independent inspector of elections for the annual meeting of stockholders held August 24, 2017, its stockholders approved all of the merger-related proposals, ...
Page: FirstPrevious ...
8
= add release to Briefcase
© 2017 Mirna Therapeutics, Inc. All Rights Reserved.